ERBB2 and breast carcinoma: Considering TTD was merely 14.9 months even in post-T period, and lapatinib treatment was identified as an independent prognostic factor in Cox-regression model (P=0.040, HR 5.069) in this study (Table 4), new therapeutic strategies for BM in HER2-positive breast cancer are urgently needed and lapatinib may be a good therapeutic option in these cases.